Literature DB >> 10989509

Polymyalgia rheumatica and giant cell arteritis.

J M Evans1, G G Hunder.   

Abstract

PMR and GCA are related conditions that seem to represent a continuum of disease. These conditions are relatively common and seem to be mediated by a cellular inflammatory response. Increasing evidence suggests an infectious cause (or causes) precipitating this immune response in genetically susceptible individuals. Whereas previously thought to affect primarily branch vessels of the aortic arch, GCA is now thought of as a disease in which proximal aortic involvement is frequent. Despite the potential for serious, even fatal complications, overall prognosis for patients with GCA or PMR is excellent. Corticosteroids remain the standard treatment, although not curative. Whereas the ESR is a useful indicator of disease activity, other markers which may be more precise such as creative protein and Il-6 seem to offer added information about disease activity.

Entities:  

Mesh:

Year:  2000        PMID: 10989509     DOI: 10.1016/s0889-857x(05)70153-8

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  12 in total

Review 1.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

2.  Relationship between histological subtypes and clinical characteristics at presentation and outcome in biopsy-proven temporal arteritis. Identification of a relatively benign subgroup.

Authors:  E J ter Borg; H C M Haanen; C A Seldenrijk
Journal:  Clin Rheumatol       Date:  2006-07-01       Impact factor: 2.980

Review 3.  Review of Giant cell arteritis.

Authors:  Joseph G Chacko; J Anthony Chacko; Michael W Salter
Journal:  Saudi J Ophthalmol       Date:  2014-11-01

4.  An immunohistochemical analysis of folate receptor beta expression and distribution in giant cell arteritis - a pilot study.

Authors:  Shirley Albano-Aluquin; Jozef Malysz; Vincent R Aluquin; Manohar Ratnam; Nancy Olsen
Journal:  Am J Clin Exp Immunol       Date:  2017-12-20

Review 5.  Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica.

Authors:  Thomas Nothnagl; Burkhard F Leeb
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  Symptoms and risk of obstructive sleep apnea in primary care patients in Jordan.

Authors:  Basheer Khassawneh; Mohammad Ghazzawi; Yousef Khader; Mousa Alomari; Zouhair Amarin; Bashar Shahrour; Mohanad Hammouda
Journal:  Sleep Breath       Date:  2008-12-10       Impact factor: 2.816

Review 7.  [Temporal arteritis (giant cell arteritis). Clinical picture, histology, and treatment].

Authors:  T Ness; C Auw-Hädrich; D Schmidt
Journal:  Ophthalmologe       Date:  2006-04       Impact factor: 1.059

8.  [Inflammatory rheumatic diseases in the elderly: rheumatoid arthritis and polymyalgia rheumatica].

Authors:  J Wollenhaupt
Journal:  Internist (Berl)       Date:  2012-09       Impact factor: 0.743

Review 9.  [Gerontorheumatology. Aspects of diagnosis, course and therapy of inflammatory rheumatic disease in advanced age].

Authors:  J Wollenhaupt
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

10.  EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).

Authors:  B F Leeb; H A Bird; G Nesher; I Andel; W Hueber; D Logar; C M Montecucco; J Rovensky; J Sautner; M Sonnenblick
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.